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Summary
BACKGROUND: We retrospectively analysed charts of
patients with blood ferritin level >5000 µg/l. The aim of
the study was to look for the likelihood of haemophagocyt-
ic lymphohistiocytosis (HLH) in these patients.
METHODS: Forty-two patients demonstrated hyperferrit-
inaemia and could be evaluated. The diagnosis of HLH was
based on a recently published HScore and an earlier dia-
gnostic algorithm.
RESULTS: According to the algorithm, 20 patients ful-
filled the criteria for a diagnosis of HLH. However, patients
with Still’s disease have macrophage activation and, in this
context, a rise in ferritin without having HLH. Fourteen pa-
tients with carcinoma, haematological malignancies or in-
fection and hyperferritinaemia remained. Signs and symp-
toms were: systemic inflammatory response syndrome
(SIRS 100%), fever (95%), cytopenia of ≥2 lines (70%),
immunosuppression (61.5%), splenomegaly (50%), elev-
ated liver enzymes (45%), lymphadenopathy (35%), hep-
atomegaly (30%). These are nonspecific parameters.
Therefore HLH may be overdiagnosed. Using the HScore,
only 10 patients had >80% probability of having HLH. Pa-
tients demonstrating cytopenia of ≥2 cell lines had a >60%
mortality rate. Time to death was 13.8 days; death was
most often due to multiorgan failure.
CONCLUSION: HScore reflects a higher specificity than
the algorithm for diagnosing HLH. The discrepancy may
indicate the difficulty that a specific marker still is missing.
Hyperferritinaemia was strongly associated with HLH in
patients with haematological or oncological malignancies.
HLH may be underdiagnosed because the majority of these
patients suffer from a severe underlying disease, which eas-
ily might suggest a flare or infection. In this population,
hyperferritinaemia and SIRS should rise suspicion because
mortality in HLH is high.
Key words: hyperferritinaemia; systemic inflammatory
response syndrome; Still’s disease; HLH; haematological
and solid neoplasm
Introduction
Markedly elevated ferritin levels in the blood may be a
marker of severe underlying disease such as haemopha-
gocytic lymphohistiocytosis (HLH) (for review see [1]).
In children, a ferritin level >10'000 µg/l has been shown
to have a 90% sensitivity and 96% specificity for a dia-
gnosis of HLH [2]. The Histiocytic Society classifies the
syndrome as primary (genetic) and secondary (reactive)
forms [3]. Genetic defects result in T-cell lymphocyte or
natural killer cell dysfunction [3, 4]. In adults, secondary
HLH or the reactive macrophage activation syndrome is
more frequent and has been described in association with
various causes, e.g. autoimmune disease, infections, neo-
plasms, drugs, etc. [5–7]. More recently, various genetic
defects causing HLH also have been described in adults
[8]. Regardless of its aetiology, dysfunctional regulation of
cytokines leads to a cytokine storm clinically resembling
systemic inflammatory response syndrome (SIRS). In
some cases this may result in multiple organ dysfunction or
failure, and even death [9]. The diagnosis of HLH is chal-
lenging owing to the lack of pathognomonic clinical and
laboratory markers. Diagnostic criteria mainly define the
primary form of the syndrome. In HLH, the serum ferritin
level may be disproportionately elevated [10]. This find-
ing contrasts to other inflammatory diseases. Hyperferritin-
aemia may be the most prominent biochemical abnormality
in patients with HLH. Additional abnormal findings in-
clude cytopenia of several cell lines, elevated concentration
of lactate dehydrogenase (LDH) and liver enzymes, hy-
pertriglyceridaemia and a low fibrinogen level. However,
all these markers are nonspecific. A rise in soluble inter-
leukin-2 (IL-2) receptor α chains (sCD25) and CD163 are
promising markers with more specificity [11, 12].
In children, the incidence of HLH or MAS is 1:800'000
in Sweden [13]. In adults, malignancy-associated HLH has
been estimated to occur in 3.6:1'000'000 patients per year
[14]. Even though its course is often lethal HLH is under-
diagnosed [15] because a flare of the underlying disease or
infection can explain many signs and symptoms of HLH.
Only enhancing the awareness and systematic measure-
ment of a cheap and easily available, specific marker of
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HLH will shed light on the real incidence of this syndrome.
For screening, ferritin seems accurate in patients with SIRS
and sepsis-like syndrome. Early diagnosis is critical in or-
der to start treatment of HLH before deterioration of the
patient’s condition. Improvement of outcome has been
demonstrated with glucocorticoids [5], etoposide [16], im-
munoglobulins (IGs) [17], anti-CD20 antibody rituximab,
ciclosporin and tacrolimus [18], etc.
The aim of the present study was to look for patients with
excessive ferritin levels who were hospitalised in a tertiary
hospital in Switzerland between 1996 and 2011. In addi-
tion, we looked for the aetiology, clinical, haematological
and biochemical parameters, and outcome in these patients.
Methods
Retrospectively, charts of patients with serum ferritin level
>5'000 µg/l admitted to the Department of Medicine of a
tertiary hospital in Switzerland were analysed. Some pa-
tients were hospitalised more than once. The first hospit-
alisation during which such an elevated ferritin level was
found, we called the patient’s index hospitalisation. Ferritin
was measured by means of the chemiluminiscence meth-
od (ECLIA) Cobas 6000 system by Roche (normal range:
13‒150 µg/l).
The diagnosis of HLH was based on the algorithm of Em-
menegger et al. [15]. There were three major screening
markers: (1) SIRS (temperature >38 °C or <36 °C, heart
rate >90 bpm, hyperventilation, white blood cells >12 G/l
or <4 G/l); (2) peripheral blood cytopenia affecting at least
two of the three blood cell lines; (haemoglobin <90 g/l,
neutrophils <1.0 G/l, platelets <100 G/l); (3) underlying
disorder increasing the risk of HLH, and in addition mor-
phological evidence of haemophagocytosis, soluble
CD163, soluble CD25, elevated liver enzymes and LDH.
The ferritin level was set arbitrarily, since in other inflam-
matory diseases ferritin levels >5'000 µg/l are rare. Spleno-
megaly, hypertriglyceridaemia, hypofibrinogenaemia, hae-
mophagcytosis in bone marrow, spleen, lymph node, or
liver and elevated sCD25 >2,400 U/l were supportive of
the diagnosis of HLH [12], but analyses were not done
routinely for our patients. A total of 44 patients had a serum
ferritin >5'000 µg/l. Data for two patients were omitted
from further analysis because only a single blood sample
was available. The remaining 42 patients were assigned
to groups A to C, according to the likelihood of them
suffering from HLH (tables 3–5). In addition, a recently
published score “HSocre” [19] (http://saintantoine.aphp.fr/
score/) included temperature, immunosuppression, organo-
megaly, hyperferritinaemia, hypofibrinogenaemia, low
triglyceride level, elevated liver enzyme, haemophagocyt-
ois in bone marrow, in order to diagnose HLH.
The approval of the ethics committee of the canton of
Luzern was obtained before data evaluation.
Results
More than 70'000 patients were hospitalised at the Luzern-
er Kantonsspital between 1996 and 2011. Forty-four pa-
tients featured a ferritin level >5'000 µg/l during this peri-
od. Ferritin testing was performed at the treating physi-
cians’ discretion and for whatever reason. Forty-two pa-
tients were enclosed for further analysis. Baseline charac-
teristics are shown in table 1.
Grouping of the patients by use of the Emmengger
algorithm [15]:
Group A (tables 1‒3)
Twenty of 42 patients did fulfil the required five of eight
criteria. Twelve patients (60%) suffered from haematolo-
gical or oncological malignancy and two patients from
an infection. Six patients (numbers 11‒16, mean age 50.2
years) fulfilled the criteria but suffered from adult Still’s
disease (one patient in addition to a myelodysplastic syn-
drome). Patients with Still’s disease have macrophage ac-
tivation and in this context hyperferritinaemia (mean
28,052 µg/l). This group represents a different entity from
classical HLH. Patient number 11 presented with a sepsis-
like condition with pancytopenia and ciprofloxacin-resist-
ant Escherichia coli. Despite appropriate antibiotic therapy
he only improved four days later, when steroids were ad-
ded. In patient 12 serology for Epstein Barr virus (EBV)
viral capsid antigen IgG and EBV IgM were positive. Ret-
Table 2: Symptoms of patients of group A.
Systemic inflammatory response syndrome 100%
Ferritin >5'000 µg/l 100%
Temperature (>38 °C or <36 °C) 95%
Cytopenia of at least two cell lines 70%
Splenomegaly 50%
Elevated transaminases 45%
Lymphadenopathy 35%
Rash 35%
Hepatomegaly 30%
Arthritis 25%
Neurological manifestation 15%
Table 1: Grouping of the patients suffering from haemophagocytic lymphohistiocytosis (HLH) using HScore and the algorithm of Emmenegger [15], fulfilling at least five of
eight required criteria: (A) with and without patients suffering from Still's disease (B) fewer than five of eight criteria and thus HLH is less probable, (C) patients most likely
suffer from another disease with liver injury.
HScore A without
Still’s disease
A Still’s Disease
only
Total A B C Total A‒C
Number of patients 10 14 6 20 6 16 42 (100%)
Mean age (years) 56.8 57.1 50.2 55.1 63.5 66.1 58.8
Sex
Female
Male
4
6
7
7
2
4
9
11
1
5
6
10
16 (38.1%)
26 (61.9%)
Ferritin max (µg/l) 122'600 122'600 80'660 122'600 45'400 23'970 122'600
Ferritin peak mean (ely s 41'484 35'396 28'052 33'193 16'750 12'976 23'237
Number of deaths 6 (60%) 9 (64.3%) 0 11 (55%) 3 (50%) 5 (31.3%) 19 (45%)
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rospectively, high numbers of EBV copies could be demon-
strated in stored serum of this patient. In our area primary
infection in adults is very rare. More frequently reactiva-
tion is seen.
Nine of the 14 HLH patients died (64%), all of them had
an underlying haemato-oncological disease. The average
timespan from hospital admission to death due to HLH was
13.8 days. Of the five survivors, four were treated with glu-
cocorticoids and one of them in addition with intravenous
immunoglobulin (IG). None received chemotherapy with
the intention of treating HLH. Two patients (10%) died of
other causes (one from progression of the underlying B-cell
lymphoma 7 months after HLH, one from a traumatic in-
tracranial haemorrhage 1 year later). Patients demonstrat-
ing cytopenia of two or three cell lines showed a high risk
for death (five of nine patients with pancytopenia and four
of five patients with bicytopenia). In contrast, all patients
solely with anaemia survived (table 3). All patients with
Still’s disease survived.
Group B (table 4)
Patients in group B had hyperferritinaemia but did not fulfil
at least five of the required eight criteria of the HLH al-
gorithm. There was, for example, a lack of various chem-
ical markers of HLH at the time of hyperferritinaemia. In
three patients an infection was confirmed by blood cultures
or at autopsy (Mycobacterium avium complex, mucormy-
cosis, and Pasteurella multocida). Three patients (50%)
died during the index hospitalisation. In contrast with use
of the criteria of the HScore [19], two patients of group B
suffered from HLH with >80% probability.
Group C (table 5)
All 16 patients of group C had liver injuries of different
aetiologies. Peak plasma ferritin levels in this group were
lower than group A and B (range 8'700 to 23'970 µg/l; me-
dian 11'660 µg/l). Liver injury (e.g. ischaemia, severe con-
gestion) may cause a rise in ferritin level without HLH. The
algorithm did not suggest HLH in this group. None of the
patients had >80% likelihood of HLH in the HScore. Five
patients (31.3%) in group C died. Three of them had liver
metastases.
HScore
The HScore selected 10 patients with hyperferirtinaemia
and a probability of >80%, and 14 of the 42 patients with
Table 3: Details of patients in group A.
No. Disease Maximum
ferritin level
(µg/l)
H Score Age years
/ sex
Cytopenia Treatment:
Steroids (S)
Intravenous
immunoglobulin
(IG)
Outcome
(survived
HLH)
I. Haematological malignancies 3 out of 10
1 Acute monocytic leukaemia (FAB M5b) 53'427 4.9 81 / F Yes (anaemia,
thrombocytopenia)
S/IG No
2 Acute myeloid leukaemia (FAB M5) 42'840 30.1 73 / M Yes (all 3 cell lines) S No
3 Myelodysplastic syndrome with transformation into acute
myeloid leukaemia
18'071 82.8 68 / F Yes (all 3 cell lines) S Yes (died of
other cause)
4 Acute myeloid leukaemia (FAB M5) 17'740 49.1 29 / M Yes (all 3 cell lines) S Yes
5 B-cell chronic lymphocytic leukaemia with transformation
into B-cell prolymphocytic leukaemia
15'590 86.8 60 / M Yes (anaemia,
thrombocytopenia)
S No
6 B-cell acute lymphoblastic leukaemia 15'295 64.2 43 / F Yes (all 3 cell lines) S/IG No
7 Chronic myelogenous leukaemia 9'470 99.4 57 / M Yes (anaemia,
thrombocytopenia)
S/IG No
8 Anaplastic T-cell non–Hodgkin’s lymphoma 122'600 99.9 45 / F Yes (all 3 cell lines) S/IG No
9 Anaplastic large cell B-cell non-Hodgkin’s lymphoma 81'500 99.9 45 / F Yes (all 3 cell lines) S/IG No
10 Large cell centroblastic B-cell non-Hodgkin’s lymphoma 64'700 90.5 46 / M Yes (all 3 cell lines) S/IG Yes (died of
other cause)
II. Systemic inflammatory disorders 2 out of 2
11 E. coli sepsis 12'495 98.8 77 / F Yes (all 3 cell lines) S Yes
12 Epstein-Barr virus infection 9'259 32.7 51 / M Yes (anaemia,
thrombocytopenia)
– Yes
III. Solid tumours 0 out of 2
13 Metastasised prostate cancer 19'090 30.1 70 / M Yes (all 3 cell lines) S No
14 Metastasised renal cell carcinoma 13'470 13.1 55 / F Yes (anaemia,
thrombocytopenia)
S No
Total 5 out of 14
IV. Still’s disease
15 No malignant disease 80'660 44.5 53 / M Yes (anaemia) S Yes
16 No malignant disease 35'720 96.5 55 / M Yes (anaemia) S/IG Yes
17 Still’s disease and myelodysplastic syndrome 19'640 4.4 75 / F Yes (anaemia) S Yes
18 No malignant disease 13'786 16.1 39 / M Yes (anaemia) S Yes
19 No malignant disease 10'390 12.4 56 / M Yes
(thrombocytopenia)
S Yes
20 No malignant disease 8'120 16.9 23 / F Yes (anaemia) S Yes
Total 6 out of 6
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<50% probability of suffering from HLH (tables 1‒5). One
patient with Still’s disease also had a 96.5% probability of
suffering from HLH although the clinical findings did not
differ from the other Still’s disease patients. Taken togeth-
er, the algorithm suggested 14 patients were suffering from
HLH and the HScore suggested 10 patients with >80%
probability of HLH. The discrepancy may be the result of
using different but still nonspecific, markers of HLH.
Discussion
During a 15 year period (1996 to 2011), 42 patients had a
high ferritin level >5'000 µg/l and 30 patients >10'000 µg/l
at our tertiary hospital in Central Switzerland. In another
single centre 43% of patients with ferritin levels >10'000
µg/l suffered from HLH [20]. According to Ma et al. [21],
after excluding sickle cell anaemia, liver disease and graft
versus host disease, HLH should be suspected in >80% of
patients with a ferritin level above that range. However, in
our series, the diagnosis of HLH was very likely in only
14 cases (12 patients with ferritin >10'000 µg/l). They ful-
Table 4: Details of patients in group B.
No. Primary disease Additional diagnosis Maximum
ferritin
level (µg/l)
H Score Age years
sex
Treatment:
Steroids (S)
Intravenous
immunoglobulin
(IG)
Outcome
(survived)
I. Haematological malignancies 1 out of 4
21 Myelodysplastic syndrome with refractory anaemia
with excess blasts
Mucormycosis 45'400 82.8 71 / M S/IG No
22 Hodgkin’s lymphoma Antifreeze poisoning,
aspiration pneumonia
10'250 59.8 68 / M S No
23 Waldenström’s disease with pancytopenia Purported urinary tract
infection, multiple
transfusions
9'795 1.8 75 / F S Yes
24 Hairy cell leukaemia MAC infection,
pseudomonal sepsis,
pulmonary aspergillosis
9'290 96.5 44 / M S/IG No
II. Solid Tumours 1 out of 1
25 Metastasised prostate cancer – 13'290 0.3 63 / M S Yes
III. Haematological disorders 1 out of 1
26 Aplastic anaemia Sepsis due to P.
multocida
12'479 18.8 60 / M – Yes
Total 3 out of 6
MAC = Mycobacterium avium complex
Table 5: Details of patients in group C.
No. Primary disease Maximum
ferritin level
(µg/l)
H Score Age
years /
sex
Outcome
(survived)
I. Hepatic metastasis 1 out of 4
27 Colon cancer 23'370 5.3 74 / M Yes
28 Breast cancer with acute liver failure 15'735 18.8 48 / F No
29 Breast cancer 13'330 0.9 72 / F No
30 Small cell lung cancer 8'700 3.7 64 / M No
II. Drug related liver injury most likely 4 out of 4
31 Phenytoin side effect likely 23'600 22.9 56 / F Yes
32 Diclofenac 23'970 47.5 50 / M Yes
33 Paracetamol and ethanol 14'880 5.9 38 / M Yes
34 Gemcitabine in breast cancer 8'340 12.4 76 / F Yes
III. Severe heart failure 1 out of 2
35 Hepatic congestion 11'540 0.2 75 / M No
36 Hepatic congestion 12'053 0.2 80 / M Yes
IV. Infection of the hepatobiliary tract 2 out of 3
37 Cholangitis and alcoholic liver disease 11'780 12.4 72 / M No
38 Chronic hepatitis B and alcoholic liver disease 9'170 0.9 52 / M Yes
39 Acute hepatitis B 8'990 75.8 36 / F Yes
40 Hepatic candidiasis after bone marrow transplantation for AML and immunosuppression 5'571 18.8 64 / F Yes
V. Haematological disorders 1 out of 1
41 Myelodysplastic syndrome and mutiple transfusions 8'480 0.4 59 / M Yes
VI. Metabolic disorders 1 out of 1
42 Haemochromatosis and relapsing fever of unknown origin 8'100 0.2 62 / M Yes
Total 11 out of 16
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filled five of eight clinico-pathological criteria of a HLH
algorithm [15] and 10 patients fulfilled the criteria of the
HScore (8 patients with ferritin >10'000 µg/l). Patients with
liver injury and very high level of ferritin were excluded
although it is possible that some also had HLH. HLH oc-
curred in our patients in fewer than 0.2‰ of all inpatients at
our hospital (70'000 patients, 500'000 inhabitants of central
Switzerland) and about 2 cases per million people, which
is below a previous estimate of 3.6 per million per year
[14]. The real incidence of HLH is probably greater, when
considering patients with plasma ferritin peaks below 5'000
µg/l and those in whom the diagnosis was never considered
or ferritin never measured. In the present study population,
the diagnosis of HLH was missed in 45% of cases during
their index hospitalisation. Since the vast majority of pa-
tients with HLH suffered from a severe underlying disease,
HLH easily is overlooked. We noticed an increased incid-
ence of HLH in our series towards the end of our observa-
tional period. This was most likely due to a growing aware-
ness of this syndrome among clinicians.
In the present series, the most common diseases associated
with HLH were haemato-oncological in origin. This con-
trasts with HLH in children, in whom genetic defects and
viral infections are the main causes of HLH [22–24]. Earli-
er reports in adults as well as in our series have shown
HLH occurring most often with malignant non-Hodgkin
lymphoma [25–27]. In our series, in addition acute myeloid
leukaemia (AML) was also a frequent underlying disease.
The cornerstones for diagnosing HLH were SIRS, marrow
haemophagocytosis and very high ferritin levels in our pa-
tients. The diagnosis of a haematological malignancy had
previously been established, with HLH being a new, un-
controlled complication. In two patients, however, HLH
was diagnosed first and the work-up elucidated the un-
derlying haematological cancer. In patient number 1 with
AML, HLH was probably triggered by induction chemo-
therapy. Soaring ferritin levels and SIRS were noted during
both cycles of induction chemotherapy. The second cycle
proved to be fatal. Delavigne [28] suggests up to 10% of
AML patients have HLH, which is triggered in the major-
ity of patients by an infection. Interestingly enough, our pa-
tients with AML and bone marrow haemophagocytosis but
without HLH did exceptionally well in terms of complete
remission. Thus, haemophagocytosis per se is not an omin-
ous sign. In HLH, uncontrolled activation of lymphocytes
and macrophages release large amounts of cytokines to
cause cytokine storm and multiorgan dysfunction. Malig-
nant haematological diseases were most frequent and these
patients did markedly worse compared with patients with a
nonmalignant cause in our series. Other series have shown
similar aetiology and an even higher fatality rate [26, 27,
29]. Outcome is worse than in children with HLH.
The second largest group of patients demonstrating hyper-
ferritinaemia in our series had Still’s disease. Already pre-
viously it has been argued that a subgroup of adult Still’s
disease might be identical with HLH [9]. HLH complicat-
ing rheumatic disorders in children has been found to fol-
low a severe course and may be fatal [30]. The mean age
of our patients with Still’s disease was lower (50 years)
compared with the HLH patients with haematological neo-
plasia (57 years). The serum ferritin level was in the same
high range in both groups. Maybe some share a common
pathway, causing clinical and laboratory findings such as
SIRS and very high ferritin level [31]. It is interesting
that the HScore suggests one patient with Still’s disease
had HLH with >80% probability. These data may reflect a
higher specificity of the HScore, which includes addition-
al criteria compared with the algorithm proposed by Em-
menegger et al. However, this discrepancy may also point
towards a fundamental difference that may exist between
patients with Still’s disease and the other patients in our co-
hort. Still’s disease represents an autoinflammatory disor-
der and activation of the innate immune system. Particu-
larly the macrophage system is an inherent component of
this entity. The distinct pathophysiology of Still’s disease
may also explain the high ferritin plasma levels that are
usually observed already during relatively mild disease. It
is therefore likely that the population of patients with Still’s
disease represents a continuum of macrophage activation
states, which is difficult to segregate into a dichotomous
model of patients with or without HLH. In addition, even
those Still’s disease patients with the highest ferritin levels
usually have a good prognosis and respond to moderate-
intensity immunosuppression. Nevertheless, ferritin levels
>10'000 µg/l may still identify a group of Still’s disease
patients with a higher probability to develop overt HLH,
which may require closer clinical and laboratory follow-up.
In our series, there were only 14% of patients with in-
fection- (EBV and E. coli) associated HLH. According to
the literature, viruses (e.g. cytomegalovirus, human im-
munodeficiency virus), bacteria (including mycobacteria),
fungi, and parasites are known to cause HLH [32]. EBV
has been described as a trigger for HLH frequently in chil-
dren and Asian adults but rarely in adults of western coun-
tries [15, 33]. It is interesting to note that the infectious
agents found in patients of group B fitted the spectrum of
known triggers of HLH (e.g. atypical mycobacteria, fungi,
Gram-negative bacteria) [32], thus raising the question, if
some of these cases, were not indeed cases with infection
related HLH.
In the present series, patients with EBV or E. coli sepsis
and HLH had a good prognosis. In contrast, 75% of pa-
tients with malignancy-associated, excessive hyperferritin-
aemia and HLH died. Peripheral cytopenia of two cell lines
or more was an ominous sign heralding death. We did not
note a correlation between other laboratory parameters and
the likelihood of progression to death. In part, this might
be due to the retrospective nature of the study and a lack
of systematic analysis of blood samples during the course
of the disease. Since hepatocytes store high level of fer-
ritin, excessive hyperferritinaemia may also occur in pa-
tients with acute hepatic injury. Severe liver injury of any
aetiology such as metastasis, hepatitis, etc. may therefore
cause a rise in serum ferritin concentration when hepatic
cytolysis occurs even without HLH [34]. Therefore the data
of patients with some kind of hepatopathy have to be inter-
preted with caution.
Conclusion
High levels of hyperferritinaemia may be an ominous sign
in adult inpatients. Excluding patients with Sill’s and liver
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disease, a majority of these patients have HLH. However,
the diagnosis is missed very often. This most likely is
due to the difficulties distinguishing it from the underlying
disease, which may mask the life-threatening HLH. In-
sufficient knowledge of the syndrome and the lack of a
pathognomonic marker of HLH delay the diagnosis and ap-
propriate treatment. A high index of suspicion in a patient
suffering from unexplained fever, cytopenia and hyperfer-
ritinaemia is still the key to recognising HLH. For screen-
ing, the analysis of ferritin should be performed in all pa-
tients with SIRS of unknown aetiology. It is cheap and easy
to measure. Until we have specific diagnostic criteria or
a specific marker, HLH remains challenging to clinicians.
Our study has limitations: it is a retrospective analysis and
blood samples were not drawn systematically and not at the
same time. Therefore statistical comparison of data might
be false negative.
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